Bristol Myers cell therapy manufacturing site gets thumbs-up from FDA
A new Bristol Myers Squibb cell manufacturing site that is expected to make the CAR-T therapy Breyanzi has received FDA approval to start production.
The pharma announced that its 244,000-square-foot cell therapy manufacturing site in Devens, MA, has gotten a OK from the FDA to begin commercial production. The manufacturing facility is the latest expansion at the BMS campus there, which already has developing, testing and manufacturing capabilities for BMS medicines. The facility has brought in 500 new employees as well.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.